During the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) to be held April 1 to 5, 2017, in Washington, D.C., scientists at Seattle Genetics are expected to present 14 presentations on advances in the development of antibody-drug conjugate or ADCs and immuno-oncology technology.
Among the multiple presentations is specific research that demonstrates potential improvements in linker chemistry for multiple payloads. This may enable development of novel ADCs, including the planned clinical program SGN-CD48A for multiple myeloma.
The company’s SGN-2FF program was selected for an oral presentation in the New Drugs on the Horizon symposium focusing on the preclinical rationale and phase 1 trial design for this small molecule immuno-oncology agent.
Seattle Genetics’ scientific leadership will also be featured in an Educational Session and a Forum focused on advances in ADC research and the value of ADCs over other drug conjugate therapeutics in the cancer treatment landscape.
“Over nearly 20 years, Seattle Genetics has continued its tradition of innovation to produce industry-leading ADC and empowered-antibody technologies designed to improve outcomes for patients with cancer,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics.
“In 14 presentations, including four orals, our new data at the AACR Annual Meeting will highlight key improvements to linker technologies for cancer cell-killing payloads, including novel auristatins and tubulysins, preclinical combination regimens with checkpoint inhibitors, and progress with our immuno-oncology therapeutic candidates.”
|April 1, 2017||Expanding the payload scope and drug load of ADCs through drug-linker design||Session #ED03, oral presentation at 2:00 p.m. ET|
|April 2, 2017||Antibody-drug conjugates containing glucuronide-tubulysin payloads display activity in MDR+ and heterogeneous tumor models||#56, poster presentation|
|April 2, 2017||Reducing toxicity of antibody-drug conjugates through modulation of pharmacokinetics||#60, poster presentation|
|April 2, 2017||Elucidating the roles of antibody pharmacokinetics and maleimide stability in the toxicology of antibody-drug conjugates||#70, poster presentation|
|April 2, 2017||Development of homogeneous dual-drug ADCs: Application to the co-delivery of auristatin payloads with complementary antitumor activities||#982, oral presentation at 4:05 p.m. ET|
|April 2, 2017||SGN-2FF: A Novel Small Molecule Inhibitor of Fucosylation with Preclinical Antitumor Activity through Multiple Immune Mechanisms||#DDT02-02, oral presentation at 3:24 p.m. ET|
|April 3, 2017||Cysteine Mutant Location Affects Chemotype Lability in Site-Specific Antibody Drug Conjugates||#LB-066, poster presentation|
|April 3, 2017||Targeted Delivery Using Antibody Drug Conjugates||#FO01, oral presentation at 5:00 p.m. ET|
|April 4, 2017||Therapeutic activity of effector function-enhanced, non-fucosylated anti-CD40 antibodies in preclinical immune-competent rodent tumor models||#3647, poster presentation|
|April 4, 2017||Superior T cell activity of a membrane-proximal binding antibody when targeting Glypican-3 with an Antibody-Coupled T cell Receptor (ACTR) armed T cell||#3762, poster presentation|
|April 4, 2017||Effect of PEG Chain length on Antibody-Drug Conjugate Tumor and Tissue Distribution in Tumor Bearing Xenograft Mice||#4075, poster presentation|
|April 4, 2017||Efficient targeting of BCMA-positive multiple myeloma cells by Antibody-Coupled T cell Receptor (ACTR) engineered autologous T cells in combination with an anti-BCMA antibody||#4605, poster presentation|
|April 4, 2017||Assessment of Myeloblast CD33 Receptor Occupancy (RO) by Vadastuximab Talirine in Patients with Acute Myeloid Leukemia (AML) Receiving Monotherapy Treatment||#CT120, poster presentation|
|April 5, 2015||Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo||#5588, poster presentation|